ES2086270T3 - Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos. - Google Patents

Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.

Info

Publication number
ES2086270T3
ES2086270T3 ES93918584T ES93918584T ES2086270T3 ES 2086270 T3 ES2086270 T3 ES 2086270T3 ES 93918584 T ES93918584 T ES 93918584T ES 93918584 T ES93918584 T ES 93918584T ES 2086270 T3 ES2086270 T3 ES 2086270T3
Authority
ES
Spain
Prior art keywords
terfenadine
metabolites
optically pure
allergic disorders
pure isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93918584T
Other languages
English (en)
Other versions
ES2086270T1 (es
ES2086270T5 (es
Inventor
James W Young
Nancy M Gray
Raymond L Woosley
Yiwang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Georgetown University
Original Assignee
Georgetown University
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27129882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2086270(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Georgetown University, Sepracor Inc filed Critical Georgetown University
Publication of ES2086270T1 publication Critical patent/ES2086270T1/es
Publication of ES2086270T3 publication Critical patent/ES2086270T3/es
Application granted granted Critical
Publication of ES2086270T5 publication Critical patent/ES2086270T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPUESTO DE FORMULA (I): DONDE Z ES COOH, COOCH{SUB,3} O CH{SUB,2}OH, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PARA USAR EN UN TRATAMIENTO ANTIHISTAMINICO QUE NO INDUZCA UNA ARRITMIA CARDIACA SIGNIFICATIVA, QUE CONSTA DE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN COMPUESTO DE FORMULA (I) A UN PACIENTE HUMANO.
ES93918584T 1992-08-03 1993-08-03 Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos. Expired - Lifetime ES2086270T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92418292A 1992-08-03 1992-08-03
US92415692A 1992-08-03 1992-08-03

Publications (3)

Publication Number Publication Date
ES2086270T1 ES2086270T1 (es) 1996-07-01
ES2086270T3 true ES2086270T3 (es) 1998-03-01
ES2086270T5 ES2086270T5 (es) 2001-02-01

Family

ID=27129882

Family Applications (3)

Application Number Title Priority Date Filing Date
ES93918584T Expired - Lifetime ES2086270T5 (es) 1992-08-03 1993-08-03 Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
ES97104837T Expired - Lifetime ES2257757T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de trastornos alergicos.
ES02006356T Expired - Lifetime ES2284740T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES97104837T Expired - Lifetime ES2257757T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de trastornos alergicos.
ES02006356T Expired - Lifetime ES2284740T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.

Country Status (24)

Country Link
US (1) US5375693A (es)
EP (4) EP0701443B2 (es)
JP (6) JP3041954B2 (es)
KR (1) KR950702420A (es)
AT (3) ATE162399T1 (es)
AU (3) AU675240B2 (es)
BR (1) BR9306841A (es)
CA (1) CA2141572C (es)
CZ (1) CZ27495A3 (es)
DE (5) DE9320925U1 (es)
DK (3) DK0815860T3 (es)
ES (3) ES2086270T5 (es)
FI (1) FI950467A (es)
GB (1) GB2284351B (es)
GR (3) GR960300024T1 (es)
HK (1) HK1045806B (es)
HU (1) HU226242B1 (es)
NO (1) NO310644B1 (es)
PL (1) PL174373B1 (es)
PT (2) PT1214937E (es)
RO (1) RO116043B1 (es)
RU (1) RU2167657C2 (es)
SK (1) SK12495A3 (es)
WO (1) WO1994003170A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ251834A (en) * 1992-05-11 1997-07-27 Merrell Dow Pharma Use of acid derivatives of terfenadine as antihistamines
DE9320925U1 (de) * 1992-08-03 1995-08-31 Sepracor Inc Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
US20020007068A1 (en) 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
EP0723958A1 (en) * 1993-06-24 1996-07-31 Albany Molecular Research, Inc. Synthesis of substantially pure terfenadine derivatives
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2449419C (en) 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
MX9706449A (es) * 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
ATE238773T1 (de) * 1997-08-26 2003-05-15 Aventis Pharma Inc Arzneimittel für die kombination piperidinoalkanol-dekongestivum
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
DE19913862C2 (de) * 1999-03-26 2003-04-10 Forschungszentrum Juelich Gmbh Verfahren zur biokatalysierten Umsetzung schlecht wasserlöslicher Substanzen
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
WO2002080857A2 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
US20040044038A1 (en) * 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4515121B2 (ja) 2004-03-15 2010-07-28 東芝テック株式会社 ワイヤドットプリンタヘッド及びワイヤドットプリンタ
JP4473021B2 (ja) 2004-03-22 2010-06-02 東芝テック株式会社 窒化層形成方法、磁気回路形成部材、アーマチュア、ワイヤドットプリンタヘッド及びワイヤドットプリンタ
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
KR20070007196A (ko) * 2004-04-26 2007-01-12 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
WO2006037042A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Fexofenadine crystal form and processes for its preparation thereof
AU2005313887B2 (en) * 2004-12-09 2011-10-27 Celgene Corporation Treatment using D-threo methylphenidate
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
ES2534588T3 (es) * 2007-04-13 2015-04-24 Southern Research Institute Terfenadina como agente antiangiogénico
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
WO2014052836A2 (en) 2012-09-27 2014-04-03 Dunman Paul M Methods and compositions for treating infection
CN115887456A (zh) 2015-03-26 2023-04-04 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
DE102017130361A1 (de) 2017-12-18 2019-07-04 Lsp Innovative Automotive Systems Gmbh Statorzahn und Stator mit guter elektrischer Isolierung und gleichzeitig sehr hoher Wärmeleitfähigkeit zur Leistungssteigerung von Elektromotoren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US880801A (en) † 1908-03-03 Harold Larsen Vibrator.
US922890A (en) † 1907-03-26 1909-05-25 Peder Joergen Hansen Stream-motor.
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4552899A (en) † 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) † 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) † 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
JP3686950B2 (ja) * 1992-04-10 2005-08-24 メレル ファーマスーティカルズ インコーポレイテッド ピペリジン誘導体類の新規な方法
NZ251834A (en) 1992-05-11 1997-07-27 Merrell Dow Pharma Use of acid derivatives of terfenadine as antihistamines
DE9320925U1 (de) 1992-08-03 1995-08-31 Sepracor Inc Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
EP0723958A1 (en) * 1993-06-24 1996-07-31 Albany Molecular Research, Inc. Synthesis of substantially pure terfenadine derivatives
HU226037B1 (en) * 1993-06-25 2008-03-28 Aventis Inc Process for producing antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives and novel intermediates
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate

Also Published As

Publication number Publication date
WO1994003170A1 (en) 1994-02-17
DK1214937T3 (da) 2007-09-17
ATE363283T1 (de) 2007-06-15
AU1842999A (en) 1999-04-29
ES2257757T3 (es) 2006-08-01
DE69316660T2 (de) 1998-05-07
NO950374D0 (no) 1995-02-01
DE9320925U1 (de) 1995-08-31
JP2000086513A (ja) 2000-03-28
GR960300024T1 (en) 1996-05-31
PT1214937E (pt) 2007-07-25
EP0815860A3 (en) 1998-01-14
EP0815860B1 (en) 2006-04-12
SK12495A3 (en) 1997-01-08
GR3026530T3 (en) 1998-07-31
ATE162399T1 (de) 1998-02-15
JPH08500348A (ja) 1996-01-16
DK0701443T3 (da) 1998-02-09
RU2167657C2 (ru) 2001-05-27
DE69334008D1 (de) 2006-05-24
ES2284740T3 (es) 2007-11-16
CA2141572A1 (en) 1994-02-17
RO116043B1 (ro) 2000-10-30
GB2284351B (en) 1996-11-27
JP2000086514A (ja) 2000-03-28
DK0815860T3 (da) 2006-08-14
EP1214937A2 (en) 2002-06-19
DE69334145T2 (de) 2008-01-24
AU4798693A (en) 1994-03-03
PL307339A1 (en) 1995-05-15
EP1214937A3 (en) 2002-10-30
DE69334145D1 (de) 2007-07-12
JP3288660B2 (ja) 2002-06-04
JP2000086515A (ja) 2000-03-28
DE701443T1 (de) 1997-01-30
FI950467A (fi) 1995-03-31
AU675240B2 (en) 1997-01-30
BR9306841A (pt) 1998-12-08
JP2000086516A (ja) 2000-03-28
HK1045806A1 (en) 2002-12-13
GB9502183D0 (en) 1995-03-22
EP0815860A2 (en) 1998-01-07
ES2086270T1 (es) 1996-07-01
DE69334008T2 (de) 2006-10-19
HU226242B1 (en) 2008-07-28
ES2086270T5 (es) 2001-02-01
EP0701443A1 (en) 1996-03-20
JP2000086512A (ja) 2000-03-28
NO950374L (no) 1995-03-29
JP3041954B2 (ja) 2000-05-15
JP3288662B2 (ja) 2002-06-04
EP0701443B1 (en) 1998-01-21
CA2141572C (en) 2001-02-06
NO310644B1 (no) 2001-08-06
DE69316660T3 (de) 2001-04-05
RU95107881A (ru) 1996-11-27
HU9500313D0 (en) 1995-03-28
GR3035417T3 (en) 2001-05-31
GB2284351A (en) 1995-06-07
JP3288661B2 (ja) 2002-06-04
EP0701443B2 (en) 2000-11-22
US5375693A (en) 1994-12-27
DK0701443T4 (da) 2000-12-18
EP1688142A1 (en) 2006-08-09
ATE322899T1 (de) 2006-04-15
AU7182296A (en) 1997-01-30
JP3037697B2 (ja) 2000-04-24
KR950702420A (ko) 1995-07-29
EP1214937B1 (en) 2007-05-30
HK1045806B (zh) 2008-03-14
PT815860E (pt) 2006-08-31
PL174373B1 (pl) 1998-07-31
DE69316660D1 (de) 1998-02-26
CZ27495A3 (en) 1996-09-11
FI950467A0 (fi) 1995-02-02
HUT71889A (en) 1996-02-28

Similar Documents

Publication Publication Date Title
ES2086270T5 (es) Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
PT920865E (pt) Utilizacao de ""norastemizole"" para o tratamento de disturbios alergicos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701443

Country of ref document: ES